Healthcare, Pharma & Life Sciences

Galway – November 04, 2026 -- Medtronic plc (NYSE: MDT) will report financial results for its second quarter of fiscal year 2027 on Tuesday, November 24, 2026. The quarter ended on Friday, October 30, 2026.

Medtronic to publish summary financials at 5:45 a.m. CT

The company will issue a news release with summary financial information at 5:45 a.m. Central Time on the day of reporting. The release will be available on Medtronic's news site.

Video webcast on results begins at 6:30 a.m. CT

A video webcast to discuss the results starts 45 minutes after the release, at 6:30 a.m. CT, and will be accessible via the company's investor relations site.

A replay and a transcript of the prepared remarks will be posted within 24 hours of the webcast. Both will be available through the Events link on the investor relations site.

Bridgewater – November 04, 2026 -- Insmed Incorporated (Nasdaq: INSM) will put management in front of investors at two healthcare conferences within a span of 15 days, starting November 16 in London.

Insmed management to present at Jefferies in London on November 16

The company will appear at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026, at 9:00 a.m. ET.

Evercore session in Coral Gables is set for December 1

Management will then present at the Evercore 9th Annual Healthcare Conference in Coral Gables, Florida, on Tuesday, December 1, 2026, at 9:10 a.m. ET.

Both presentations will be webcast live and archived for 30 days

Both events will be webcast live through the investor relations section of Insmed's website. Each webcast will remain archived for 30 days after the live event ends.

BOSTON – November 04, 2026 -- Sanofi ranked first in the 2026 CNS Summit Digital Innovation Index and placed in the top three in all three categories: research, clinical development and commercial. The rankings, developed with IDEA Pharma, a division of SAI MedPartners, were revealed on the CNS Summit 2026 main stage at Encore Boston Harbor.

Index ranks 30 pharma companies on public digital initiatives and investments

Now in its 11th year, the Index scores the top 30 pharmaceutical companies on digital innovation. It draws only on publicly reported initiatives and investments from July 2025 through July 2026.

The 2026 top 10 are Sanofi, Eli Lilly, AstraZeneca, Chugai, Roche, Bristol Myers Squibb, Novo Nordisk, Johnson & Johnson, Boehringer Ingelheim and Merck KGaA.

Roche, Novo Nordisk and Recursion lead individual categories

Roche led the commercial category and Novo Nordisk led clinical development. Recursion led research.

Brussels – November 04, 2026 -- The head of Germany's pharmaceutical industry association BPI has said the EU is not prepared for a health crisis, calling European and national policy inadequate for the current geopolitical tensions.

BPI Chairman Oliver Kirst made the remarks at the association's autumn reception at the Bibliothèque Solvay in Brussels. He described the lack of crisis resilience as irresponsible and said EU action is too slow and too bureaucratic.

Critical Medicines Act still awaits formal adoption

Kirst named the Critical Medicines Act (CMA) as the prime example of EU hesitation. He called its aim of returning critical medicine production to Europe right and urgent. The act, he noted, has been debated for a long time and still has to be formally adopted.

Chairman lists open questions on production, storage and protection

Kirst said too many questions remain unanswered:

Singapore – November 04, 2026 -- The National University Health System (NUHS), Singtel and Ericsson have signed a Memorandum of Understanding to launch the National University XG AI Centre (NXAC), which the partners describe as the world's first 6G AI centre dedicated to healthcare and Singapore's first translational research and development centre.

Singtel and Ericsson become founding partners of NXAC

NUHS will provide clinical, academic and research leadership. Ericsson will contribute expertise in mobile network technologies, network architecture and future 6G research, while Singtel will supply advanced network deployment and services expertise.

NXAC will act as a testbed where industry partners work alongside clinicians, nurses and operations teams to develop and evaluate technologies in a working hospital. The programme starts on 5G and 5G-Advanced and is designed to evolve towards early 6G.

Ljubljana – November 04, 2026 -- Fotona has created a new Vice President, EMEA General Manager position and filled it with Miha Debelak, who took up the role on November 1, 2026 and reports directly to President and CEO Jeff Duchemin.

Debelak takes charge of direct entities and distributor markets across EMEA

Debelak will lead commercial operations across Europe, the Middle East and Africa. His remit covers both Fotona's direct entities and its distributor markets in the region.

The laser-based medical and aesthetic technology maker describes the post as newly created. It links the move to rising demand for its technologies across EMEA and to its long-term growth strategy.

Etoy, Switzerland – November 04, 2026 -- Sunstar, the Japanese-founded oral healthcare company, has launched the Sunstar Mouth-to-Body Health Institute, a global research body built to test how oral health affects disease elsewhere in the body, after more than 40 years of funding oral-systemic research.

Institute links dentistry, medicine and public health under one research platform

The Institute will bring together researchers, clinicians and scientific leaders from dentistry, medicine, microbiology, immunology, nutrition, behavioural science and public health. Its initial research covers periodontal health science, the oral microbiome and the connection between oral health and overall health.

A Global Scientific Advisory Board will provide scientific guidance and oversight, supported by Institute members from multiple disciplines.

GALWAY – November 03, 2026 -- Medtronic's Symplicity Spyral renal denervation (RDN) system cut office systolic blood pressure by 18.2 mmHg at six months in the SPYRAL AFFIRM post-approval study, with no increase in antihypertensive medication. The company also received U.S. FDA approval to update the device's labeling with additional clinical data.

SPYRAL AFFIRM data show significant reductions across three blood pressure measures

Six-month results in the U.S. primary endpoint cohort were compared with a prespecified performance goal. Against baseline, patients recorded the following changes, all at p<0.0001:

WASHINGTON – November 03, 2026 -- The President has signed the ACT for ALS reauthorization bill into law, extending the program for five years and committing up to an additional $500 million to ALS research infrastructure and investigational treatment access, according to patient advocacy group I AM ALS.

Senate passes bill by unanimous consent hours before the law expires

The Senate approved the reauthorization by unanimous consent with only hours left before the existing law lapsed. The House had already gone home early. The original ACT for ALS Act was co-authored by I AM ALS in 2021 to close a gap in access to investigational treatments.

Sponsors of the reauthorization are Senators Coons (D-DE) and Murkowski (R-AK) and Representatives Quigley (D-IL-05) and Calvert (R-CA-41). Calvert co-chairs the bipartisan ALS Caucus.

TORONTO – November 03, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL; TSX: CRDL) has entered into an at-the-market program that lets it sell up to US$75 million of common shares through Jefferies LLC to fund late-stage cardiac drug development.

Cardiol restricts ATM share sales to U.S. trading venues

Shares will be sold in ordinary brokers' transactions on the Nasdaq Capital Market or other U.S. trading markets at prevailing market prices. No shares will be sold through the Toronto Stock Exchange or elsewhere in Canada.

Sales will proceed under a prospectus supplement dated November 3, 2026. The supplement attaches to Cardiol's Canadian and U.S. base shelf prospectuses, both dated September 15, 2026. The U.S. base prospectus forms part of a Form F-10 registration statement that became effective on September 16, 2026.